Paget's disease of bone in 14 British towns.

The radiological prevalence of Paget''s disease was studied in 14 towns. Routine radiographs showed that the disease was present in 5.4% of people aged 55 years and over. The disease was more prevalent in men than in women at all ages, and the prevalence increased with age. The three Lancashire towns studied (Preston, Bolton, and Blackburn) had higher rates than elsewhere. This probably reflects a real geographical variation in the prevalence of Paget''s disease in England and Wales.     

Paget's disease of bone: the Lancashire focus.

The radiological prevalence of Paget''s disease of bone has been studied in 31 towns in Britain. A remarkably localised area of high prevalence has been shown in Lancashire. Although environmental influences seem dominant in the aetiology of the disease, no hypothesis about the environmental cause of the Lancashire focus can be advanced.     

Chronic treatment of Paget's disease of bone with synthetic human calcitonin.

Twelve patients with Paget''s disease of bone were treated with synthetic human calcitonin for seven to 26 months (mean 15.3 months). This group included six patients who had previous therapy. Eleven of the 12 patients experienced relief of the symptoms associated with Paget''s disease. The initial therapy of synthetic human calcitonin 0.5-1.0 mg subcutaneously was administered daily until the alkaline phosphatase had declined to a plateau response; the dose was then decreased to thrice weekly. The major biochemical findings were a 47 percent fall in serum alkaline phosphatase and a comparable decline in 24-hour urinary hydroxyproline. Two subjects discontinued therapy because of side effects; persistent nausea and vomiting in one and a cutaneous allergic reaction in the other. Other side effects were minor. Preliminary results suggest that some patients will maintain the same biochemical response on the reduced dose but that this is not predictable by pre-treatment data. We conclude that synthetic human calcitonin is a safe and effective treatment for Paget''s disease of bone. Preliminary results suggest that the dose and frequency of administration of this agent must be individualized.     

Radiological prevalence of Paget's disease of bone in British migrants to Australia.

The radiological prevalence of Paget''s disease among migrants from the United Kingdom to Australia was higher than in a comparable Australian resident population but lower than in a British resident population. A probable explanation is that the migrants carry with them the higher UK risk of developing the disease.     

Effect of calcitonin treatment on deafness due to Paget's disease of bone.

Seventeen patients with Paget''s disease of the skull and deafness were followed for nine to 18 months. Patients who received calcitonin treatment showed less deterioration in hearing than untreated patients. Calcitonin treatment may retard the progression of deafness in Paget''s disease, and further studies are indicated.